Advertisement
"For the last 60 years, it has been well established that cancer andnutrition are intrinsically connected," said Yuri Nikolsky, CEO of GeneGo andthe grant's PI. "However, this knowledge is scattered in thousands of sources,which are difficult to annotate and categorize. We will assemble the firstspecialized database on the topic and develop automated tools for dataanalysis. The new platform will be primarily targeting healthcareprofessionals and nutritionists."
Advertisement
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound basedpathway analysis, cheminformatics & bioinformatics software for life scienceresearch. The original computational MetaDiscovery(TM) platform allows anintegration and expert analysis of different kinds of experimental data (mRNAexpression, proteomics, metabolomics, microRNA assays and other phenotypicdata) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics)within the framework of curated biological pathways and networks. GeneGo'sflagship product, MetaCore 5.0(TM), assists pharmaceutical scientists in theareas of target selection and validation, data mining in biology,identification of biomarkers for disease states and toxicology. The secondproduct, MetaDrug 5.0(TM) is designed for prediction of human metabolism,toxicity and biological effects for novel small molecules compounds.MetaBase(TM) represents the knowledge base for MetaCore.
For more information, please visit the company's web site athttp://www.genego.com.
SOURCE GeneGo, Inc.
